Previous Article | Next Article 
Journal of Clinical Microbiology, June 2000, p. 2227-2231, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Comparison of Seven Tests for Serological Diagnosis
of Tuberculosis
Sudha
Pottumarthy,
Virginia
C.
Wells, and
Arthur J.
Morris*
Department of Microbiology, Green Lane and
National Women's Hospitals, Auckland, New Zealand
Received 23 September 1999/Returned for modification 19 November
1999/Accepted 29 February 2000
 |
ABSTRACT |
Seven serological tests, two immunochromatographic tests, ICT
Tuberculosis and RAPID TEST TB, and five enzyme-linked
immunosorbent assays, TUBERCULOSIS IgA EIA, PATHOZYME-TB complex,
PATHOZYME-MYCO IgG, PATHOZYME-MYCO IgA, and PATHOZYME-MYCO IgM,
were evaluated simultaneously with 298 serum samples from three groups
of individuals: 44 patients with active tuberculosis, 204 controls who
had undergone the Mantoux test (89 Mantoux test-positive and 115 Mantoux test-negative controls), and 50 anonymous controls. The
sensitivities of the tests with sera from patients with active
tuberculosis were poor to modest, ranging from 16 to 57%. All the
tests performed equally with sera from subgroups of those with active
tuberculosis, those with pulmonary (33 patients) versus extrapulmonary
(11 patients) disease, and those who were smear positive (24 patients)
versus smear negative (12 patients) (P > 0.05). The
specificities of the tests ranged from 80 to 97% with sera from the
Mantoux test controls and 62 to 100% with sera from the anonymous
controls. The TUBERCULOSIS IgA EIA had the highest sensitivity (57%)
with sera from patients with active tuberculosis, with a high
specificity of 93% with sera from the Mantoux test controls, but a
very poor specificity of 62% with sera from the anonymous controls.
Overall, ICT Tuberculosis followed by PATHOZYME-MYCO IgG had the best
performance characteristics, with sensitivities of 41 and 55%,
respectively, with sera from patients with active tuberculosis and
specificities of 96 and 89%, respectively, with sera from the Mantoux
test controls and 88 and 90%, respectively, with sera from the
anonymous controls. By combining all the test results, a maximum
sensitivity of 84% was obtained, with reciprocal drops in
specificities to 55 and 42% for the Mantoux test controls and
anonymous controls, respectively. The best combination was that of ICT
Tuberculosis and PATHOZYME-MYCO IgG, with a sensitivity of 66% and a
specificity of 86% for the Mantoux test controls and a sensitivity and
specificity of 78% for the anonymous controls. While a negative result
by any one of these tests would be useful in helping to exclude disease
in a population with a low prevalence of tuberculosis, a positive result may aid in clinical decision making when applied to symptomatic patients being evaluated for active tuberculosis.
 |
INTRODUCTION |
Tuberculosis has been declared a
global emergency. The mainstay for its control is the rapid and
accurate identification of infected individuals. The simplest rapid
method is the detection of acid-fast bacilli by microscopy. However, 40 to 60% of patients with pulmonary disease and ~75% of patients with
extrapulmonary disease are smear negative, and in this situation even
contemporary culture methods take several weeks to become positive
(7, 11, 12). Therefore, a number of alternative diagnostic
tests that use molecular, chromatographic and immunological methods
have been developed. While molecular methods overcome the insensitivity of the smear method and the time required for culture, they depend upon
retrieval of a specimen from the site of infection. This is often
difficult in cases of tuberculosis in children and in some cases of
extrapulmonary disease.
Immunological methods use the specific humoral or cellular responses of
the host to infer the presence of infection or disease. They do
not require a specimen from the site of infection. Numerous serological tests that use various antigens, such as secreted and heat
shock proteins, lipopolysaccharides, and peptides, have been developed
(2). These tests use various modifications of enzyme-linked immunosorbent assay (ELISA) or
immunochromatographic methods to detect different antibody classes.
Only rarely has more than one serological test been evaluated with sera
from the same group of individuals (2, 4, 10). We have
evaluated seven serological tests to determine their performances with
sera from three groups of individuals.
 |
MATERIALS AND METHODS |
Study population.
Over 16 months, May 1997 to September
1998, 298 individuals were evaluated. All were human immunodeficiency
virus negative. They comprised three groups: 44 patients with active
tuberculosis, 204 controls who had undergone the Mantoux test, and 50 anonymous controls. The patients had a median age of 37 years (age
range, 15 to 81 years), and 22 (50%) were males. Of the 44 patients
with active tuberculosis, 33 (75%) had pulmonary disease and 11 (25%) had extrapulmonary disease. Extrapulmonary diseases included
lymphadenitis (four patients), disseminated disease (four patients),
pleural disease (two patients), and peritoneal tuberculosis (one
patient). Thirty-six (82%) patients had culture-proven disease, with
24 being smear positive and 12 being smear negative. For the eight culture-negative patients the diagnosis was made on the basis of
clinical, radiographic, and histologic findings and response to
antituberculous treatment. Sera were obtained from these patients within days of their admission to the tuberculosis ward and from almost
all patients before initiation of antituberculosis treatment.
Mantoux test controls included 146 immigrants from countries with a
high prevalence of tuberculosis (118 New Zealand quota refugees and 28 asylum seekers undergoing screening for infectious diseases), 38 health
care workers undergoing employment screening at the occupational health
clinics of Auckland and Green Lane Hospitals, and 20 microbiology staff
from these hospitals and a community laboratory in Auckland. This group
had a median age of 30 years (age range, 9 to 72 years), and 95 (47%)
were males. A total of 193 of 204 (94%) of the Mantoux test controls
had received the Mycobacterium bovis BCG vaccine. The
Centers for Disease Control and Prevention interpretative criteria for
positive Mantoux test results were followed (3). A total of
115 (56%) individuals were Mantoux test negative, and on the basis of
clinical and radiological findings no individuals in this group had
active tuberculous disease. The anonymous control group included sera
from 50 individuals; these samples were selected at random from blood
samples submitted for routine biochemistry testing from general adult
medical and surgical wards. Sera from patients from our tuberculosis
ward were not included. As the prevalence of tuberculosis in these patients is very low, for the purpose of analysis they were regarded as
not having active disease.
Sera were stored at

70°C. All the kits were tested simultaneously.
Testing was performed according to each manufacturer's
instructions.
Immunochromatographic tests.
The ICT Tuberculosis diagnostic
kit was provided by ICT DIAGNOSTICS (Balgowlah, New South Wales,
Australia). The principle of this test has been described previously
(5). In brief, five highly purified antigens (including one
of 38 kDa) secreted by Mycobacterium tuberculosis during
active infection are immobilized in four lines on the test strip. The
test detects the presence of immunoglobulin G (IgG) antibodies to these
antigens. A total of 30 µl of serum is added to a blue pad and then
diffuses along the test strip. When the test card is closed, anti-human
IgG attached to colloidal gold particles binds to any bound human IgG
antibodies, producing one or more pink lines. The presence of one or
more pink lines in the strip's test area is considered a positive test result.
The RAPID TEST TB, provided by QUORUM DIAGNOSTICS (Vancouver, British
Columbia, Canada), is a one-step colored immunochromatographic
assay.
It detects antibodies to the recombinant 38-kDa antigen
from
M. tuberculosis expressed in and purified from
Escherichia coli. A total of 100 µl of serum is added to the reaction tube,
and the test strip is placed into the tube, which is then capped.
After
15 min of incubation, the presence of two colored bands
is considered a
positive test
result.
ELISAs.
TUBERCULOSIS IgA EIA, provided by KREATECH
Diagnostics (Amsterdam, The Netherlands), detects IgA antibody to a
mycobacterial Kp90 immuno-cross-reactive antigenic compound (ImCRAC). A
total of 100 µl of diluted (1:400) serum was distributed in
microtiter wells, and the plate was incubated at 37°C in a dark humid
environment for 60 min. Unbound serum components were removed by
washing with a buffer solution. The wells were subsequently incubated
with 100 µl of peroxidase-labeled anti-human IgA conjugate at 37°C in a dark humid environment for 60 min. After another wash cycle, 100 µl of peroxidase substrate, tetramethylbenzidine containing hydrogen
peroxide, was added to the wells. The colorimetric reaction proceeded
in the dark for 30 min at room temperature (20 to 25°C) until 100 µl of stop agent was added. The absorbance values at 450 nm were
recorded with an automatic reader system. The cutoff optical density
(OD) was derived from the mean of the three cutoff control OD readings
(as recommended by the manufacturer). The ratio of the OD for the
unknown serum sample to the cutoff OD was used to interpret the results.
The PATHOZYME-TB complex test kit was provided by OMEGA DIAGNOSTICS
LIMITED (Alloa, Scotland). The kit detects serum IgG antibody
to a
recombinant 38-kDa antigen from
M. tuberculosis expressed
in
and purified from
E. coli. This kit is specific for the
diagnosis
of disease due to
M. tuberculosis complex. The
procedures were
similar to those described for TUBERCULOSIS IgA EIA,
except that
the sera were diluted 1:50, the second incubation was for
30 min
rather than 60 min, the first and second incubations were not
in
a dark humid environment, and the third incubation was in the
dark at
37°C for 15 min. Three standards (with 2, 4, and 16 serounits/ml)
were provided for the generation of a semilogarithmic reference
curve.
Because the sera were diluted 1:50, the units extrapolated
from the
reference curve were multiplied by 50 to obtain serounits
for result
interpretation.
The individual PATHOZYME-MYCO IgG, IgA, and IgM assay kits were
provided by OMEGA DIAGNOSTICS LIMITED. The three assays measure
the
levels in serum of IgG, IgA, and IgM antibodies, respectively,
to two
antigens; lipoarabinomannan (LAM) and recombinant 38-kDa
antigen. These
kits detect infection due to
Mycobacterium species.
The
procedures were identical to those described for PATHOZYME-TB
complex
except that the sera were diluted 1:100 rather than 1:50
and all three
incubations were at room temperature. For the IgG
and IgA assays three
standards (with 2, 4, and 16 serounits/ml)
were provided for generation
of a semilogarithmic reference curve.
Because the sera were diluted
1:100, the units extrapolated from
the reference curve were multiplied
by 100 to obtain serounits
for result interpretation. For the IgM
assay, low- and high-positive
control sera were provided. The OD of the
low-positive control
was used for the interpretation of the
results.
Statistical analysis.
Sensitivities, specificities, and
predictive values were calculated by standard methods. Sensitivity was
defined as the ability to detect cases of active tuberculosis.
Specificity was defined as the ability to be negative for the Mantoux
test and anonymous controls, who, for the purposes of analysis, were
considered to be free of active tuberculosis. The differences in the
performances of the tests were analyzed by the
2 test.
Positive and negative predictive values were calculated for different
prevalences of disease: 11 per 100,000 population (0.01%) as the
overall rate of new cases of tuberculosis in New Zealand in 1995; 125 per 100,000 population (0.125%) as the highest rate of tuberculosis in
those of other ethnic background, mainly Southeast Asian people with
tuberculosis; and 76% as the prevalence of disease among patients
being evaluated for tuberculosis in our tuberculosis ward (8,
9).
 |
RESULTS |
Performance of the serological tests with sera from patients with
active tuberculosis.
For the 44 patients with active tuberculosis,
the sensitivities of the assays ranged from 16 to 57% (Table
1). For the 33 patients with pulmonary
tuberculosis, the sensitivities of the assays ranged from 15 to
58%, with the lowest being for PATHOZYME-TB complex (15%) and
the highest being for TUBERCULOSIS IgA EIA and PATHOZYME-MYCO IgG (58% each). For the 11 patients with
extrapulmonary disease, the sensitivity ranged from 9 to 55%, with the
lowest being for PATHOZYME-MYCO IgM (9%) and the highest being for
TUBERCULOSIS IgA EIA (55%). For the 24 smear-positive patients,
the sensitivity ranged from 17 to 63%, with the lowest being for
PATHOZYME-TB complex (17%) and the highest being for PATHOZYME-MYCO
IgG (63%). For the 12 smear-negative patients, the sensitivity ranged
from 17 to 58%, with the lowest being for PATHOZYME-TB complex and PATHOZYME-MYCO IgM (17% each) and the highest being for TUBERCULOSIS IgA EIA (58%). The differences between the performances of the assays
were not statistically significant between the groups, analyzed as
either pulmonary versus extrapulmonary cases or smear-positive versus smear-negative cases (P > 0.05) (Table 1).
Performances of the seven tests with sera from the control
groups.
For the 204 Mantoux test controls, the test positivity
rate ranged between 3 and 20%, with the lowest being for PATHOZYME-TB complex (3%) and the highest being for PATHOZYME-MYCO IgM (20%) (Table 2). Mantoux test-positive
individuals had higher positivity rates than the Mantoux test-negative
individuals (except with the PATHOZYME-MYCO IgG and IgM kits), and the
difference was statistically significant for RAPID TEST TB,
TUBERCULOSIS IgA EIA, PATHOZYME-TB complex, and PATHOZYME-MYCO
IgA (P < 0.05). For the 50 anonymous controls,
the test positivity rate ranged between 0 and 38%, with the lowest
being for PATHOZYME-MYCO IgM (0%) and the highest being for
TUBERCULOSIS IgA EIA (38%) (Table 2).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Performances of seven serological tests with sera from
those with known Mantoux test results and anonymous controls
|
|
Sensitivities, specificities, and predictive values of the
serological tests.
For the 44 patients with active tuberculosis,
the sensitivities of the serological tests were poor to moderate,
ranging from 16 to 57% (Table 3). The specificities of the tests for
the Mantoux test controls ranged from 80 to 97% (Table
3). The specificities of the tests for
the anonymous controls were poor, ranging from 62 to 100%, and for
five tests it was
90% (Table 3). Because the Mantoux test group was
the larger of the two control groups and was known definitely not to
contain individuals with active tuberculosis, the predictive values
were calculated by using the data for the Mantoux test control group.
All seven tests had excellent negative predictive values (99.9%) at
either a 0.01% prevalence of tuberculosis (the overall rate of
tuberculosis in New Zealand) or a 0.1% prevalence of tuberculosis (the
highest rate of tuberculosis analyzed in an ethnic group)
(8), while the positive predictive value was very poor
(
1%) (Table 4). At a prevalence of
76% (prevalence of disease in patients admitted for evaluation to our
tuberculosis ward) (9), all tests had good positive
predictive values, which ranged from 74 to 97%, but had poor negative
predictive values (
41%) (Table 4).
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Positive and negative predictive values for the seven
serological tests at different prevalences of tuberculosis
|
|
Combination of results obtained by the seven tests.
Different
combinations of results obtained by the immunochromatographic tests and
the ELISAs were analyzed to maximize the sensitivity (Table
5). A maximum sensitivity of 84% was
obtained when the results of all seven tests were combined, but there
were decreases in specificities for the Mantoux test controls and the anonymous controls to 55 and 42%, respectively (Table 5). The best
combination was that of ICT Tuberculosis and PATHOZYME-MYCO IgG, with a
sensitivity of 66% and with specificities of 86 and 78% for the
Mantoux test and anonymous controls, respectively. Combination of
results of the PATHOZYME-MYCO IgG, IgA, and IgM panel of tests also
increased the sensitivity to 66%, but the specificities decreased for
the Mantoux test and anonymous controls to 67 and 70%, respectively
(Table 5).
 |
DISCUSSION |
More than 100 years ago, in 1898, Arloing reported the first
serodiagnostic test for tuberculosis, an agglutination test, just 16 years after Koch's identification of the tubercle bacillus. For the
next eight decades numerous serological techniques were evaluated, but
they gave poor results due to the cross-reactive nature of the antigens
used. Since the introduction of ELISA in 1972 and the availability of
monoclonal antibodies as well as purified antigens, the serological
diagnosis of tuberculosis has become more promising (6, 7).
The 38-kDa antigen, a phosphate-binding protein, has been identified as
the immunodominant antigen in smear-positive pulmonary tuberculosis and
a potential reagent for use in screening for infectious tuberculosis
(2, 13). This antigen is common to six of the seven tests
that we evaluated, the exception being the TUBERCULOSIS IgA EIA, which
uses the Kp90 ImCRAC antigen.
The sensitivities and specificities of the seven tests varied widely,
with sensitivities ranging from ~20 to 60% and specificities ranging
from ~65 to 100%. The sensitivities of the tests were generally
lower than those obtained by other investigators (4, 5,
14; B. Lopez, N. Masciotra, and L. Barrera, Tubercle Lung Dis. 77[Suppl. 2]:119 [abstract], 1996).
Evaluation of a previous version of ICT Tuberculosis (which contained
only the 38-kDa antigen) with sera from 152 patients with active
pulmonary tuberculosis in China by Cole et al. (5) showed a
sensitivity of 89% for smear-positive patients and a sensitivity of
74% for smear-negative patients, with a specificity of 93%
(5). For the TUBERCULOSIS IgA EIA, various results have been
reported (1, 4). While Alifano et al. (1)
reported a sensitivity of 70% for 88 patients with microbiologically
confirmed pulmonary tuberculosis, with a specificity of 92%, Chiang et
al. (4), using the cutoff recommended by the manufacturer,
reported a sensitivity of 80% for 312 patients with active pulmonary
tuberculosis but a very low specificity (42%) which was improved to
66% by adjusting the cutoff, but with a reduction in sensitivity to
63%. Lopez et al. (Tubercle Lung Dis. 77[Suppl.
2]:119 [abstract], 1996) evaluated two of the PATHOZYME
ELISAs, PATHOZYME-TB complex and PATHOZYME-MYCO IgG, with sera from 26 smear-negative patients and reported sensitivities of 40 and 42%,
respectively, with specificities of 96%.
A higher rate of seropositivity for the smear-positive group compared
to that for the smear-negative group has been attributed to the higher
bacillary loads in smear-positive patients, resulting in a greater
exposure to antigen and thus a more vigorous antibody response (1,
6). Similar to other investigators, we observed generally higher
sensitivities for the smear-positive group than for the smear-negative
group and for the pulmonary infection group than for the extrapulmonary
infection group (6, 10, 14). These differences, however, did
not reach statistical significance for either group. The assays could
therefore be useful in diagnosing more difficult forms of tuberculosis,
i.e., extrapulmonary and smear-negative tuberculosis. However, as the
number of patients in our study was small, a larger number needs to be
studied to confirm our findings.
Mantoux test-positive controls were more often antibody positive than
the Mantoux test-negative controls. This was statistically significant
for four of the seven tests. Most of the Mantoux test controls
(~95%) had received the M. bovis BCG vaccine in the past. Three of the seven antigens used in the tests, the 38-kDa, Kp90 ImCRAC,
and LAM antigens, are not specific for M. tuberculosis and
are present in M. bovis BCG as well (1, 5, 6).
While M. bovis BCG expresses the 38-kDa antigen, it is
present at only 1/10 of the concentration at which it is found in
M. tuberculosis; thus, the antibody response from BCG
vaccination is neither expected to be very high nor persist for very
long (5). Similarly, IgA antibodies to Kp90 are reported to
occur only in patients with tuberculosis (1). However, Zhou
et al. (14) reported a 9% seropositivity rate for healthy
BCG-vaccinated children when their sera were tested by the ICT
Tuberculosis test. Those investigators speculated that while it could
be due to residual antibody to recent BCG vaccinations in children, it
was more likely to be due to primary tuberculosis infection
(14). Cole et al. (5) reported that 1 of 30 healthy BCG-vaccinated adult controls had a faint positive response by
the ICT Tuberculosis test and attributed it to the possibility of a
subclinical infection (5). Similarly, Alifano et al.
(1) observed the production of anti-Kp90 IgA in healthy
Mantoux test-positive and -negative subjects and hypothesized that it
could be due to clinically silent infection with environmental mycobacteria, as Kp90 is not species specific (1).
The seropositivity rates of the tests for the anonymous controls, i.e.,
general medical and surgical adult patients, were generally higher than
those for the Mantoux test controls and ranged from 0 to 40%.
Positivity rates of 9 and 12% for controls with nontuberculous lung
diseases have been reported for ICT Tuberculosis (5, 14).
This has been attributed to the fact that damaged lung tissues in
patients with these conditions allow the entry of invasive organisms
like tubercle bacilli into the tissues (5). Alifano et al.
(1) reported a 14% false-positivity rate for TUBERCULOSIS
IgA EIA for controls with nontuberculous lung diseases and attributed
it to the disorders in the immune response that occur in the course of
these diseases. Similarly, Chiang et al. (4) reported high
positivity rates of 53 and 49% for the fibrocalcified tuberculosis
group and 19 and 34% for the joint group of healthy controls and
nontuberculous pulmonary diseases for the 38-kDa IgG ELISA and the
TUBERCULOSIS IgA EIA, respectively.
The diagnostic value of a given test in clinical practice depends on
its positive and negative predictive values (4). These values vary markedly with the prevalence of the disease in a given community (7). With the very low prevalence of tuberculosis in New Zealand, i.e., 0.01% in the general population and 0.1% in the
subgroup with the highest rate, any one of the seven tests would
provide a good negative predictive value for exclusion of the disease,
while a positive result would be unhelpful. In contrast, if used with
patients admitted to our tuberculosis ward for evaluation, among whom
the prevalence of active disease in those being evaluated for active
tuberculosis is 76% (9), the high positive predictive values of tests would make a positive test result useful in
strengthening the clinical suspicion, but a negative result would be
less useful. Thus, these tests could potentially be used for those
subgroups of patients with tuberculosis from whom specimens are hard to obtain, i.e., those with extrapulmonary and childhood tuberculosis and
smear-negative patients, to aid in clinical decision making.
Investigators have recommended improving the performance values of the
tests by either adjusting the cutoff values or combining the results of
different tests (2, 4, 11). Because two of the tests that we
evaluated were immunochromatographic assays, we tried using different
combinations of the seven tests to maximize the sensitivity. Even by
combining the results of all the tests, i.e., tests with seven antigens
in various combinations, and detecting three different classes of
antibodies, a sensitivity of 100% could not be achieved, and a maximum
sensitivity of 84% with a substantial loss of specificity to
55%
was obtained. The sensitivities of tests with antibodies to single
antigens have been reported to be ~75% at best for patients with
smear-positive tuberculosis (2). Even by combining
serological responses to several antigens, sensitivity is rarely said
to exceed 90%, due to either a lack of immune responsiveness based on
the HLA phenotype, a predominant Th1 (T-helper) immune response, or the
formation of immune complexes that make the antibody unavailable
(2).
Evaluation of the seven tests simultaneously with sera from the same
population allowed us to compare the tests directly. All the tests were
user friendly, and the results were obtained within 6 h. Unlike
the five ELISAs, which required the necessary equipment and some
technical expertise, the two immunochromatographic tests, ICT
Tuberculosis and RAPID TEST TB, required no special equipment and
little or no technical skill and answers were obtained within 30 min.
Conclusion.
We evaluated seven serological tests with sera
from three groups of individuals: patients with active tuberculosis and
two control groups. Even the best of the tests had a modest sensitivity of
60% for the detection of active tuberculosis. The tests had good
specificities for the Mantoux test controls but poor specificities for
the anonymous controls. The diagnostic values of these tests depend on
the context of their use. While a negative result would be useful in
excluding disease in a population with a low prevalence of
tuberculosis, a positive result could potentially aid in clinical decision making when used with sera from a group of selected
symptomatic patients when there is a moderate to high degree of
clinical suspicion of tuberculosis.
 |
ACKNOWLEDGMENTS |
We thank Adrian Harrison, Lester Calder, Martin Reeves, Alison
McCleod, Tony Wansborough, Chris Walls, Noel Karalus, the staff of the
Green Lane Hospital tuberculosis ward, the hospital occupational health
clinics, and the staff of the Mangere Refugee Resettlement Centre for
help with the study. We thank the immigrants, microbiology laboratory,
and staff attending the occupational health clinics for participation.
We also thank ICT DIAGNOSTICS, QUORUM DIAGNOSTICS, KREATECH
Diagnostics, and OMEGA DIAGNOSTICS LIMITED for providing the tests.
Erin Cooke, Pharmaco, Auckland, New Zealand, provided valuable help in
performing the tests, and Micheal Backhurst performed the statistical analysis.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Microbiology
Laboratory, Green Lane Hospital, Green Lane West, Auckland 1003, New
Zealand. Phone: (649) 630-9943 ext. 3935. Fax: (649) 630-9785. E-mail: arthurm{at}ahsl.co.nz.
 |
REFERENCES |
| 1.
|
Alifano, M.,
R. D. Pascalis,
M. Sofia,
S. Faraone,
M. D. Pezzo, and I. Covelli.
1997.
Evaluation of IgA-mediated humoral immune response against the mycobacterial antigen P-90 in diagnosis of pulmonary tuberculosis.
Chest
111:601-605[Abstract/Free Full Text].
|
| 2.
|
Bothamley, G. H.
1995.
Serological diagnosis of tuberculosis.
Eur. Respir. J.
8(Suppl. 20):676s-688s.
|
| 3.
|
Centers for Disease Control and Prevention.
1994.
Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare facilities.
Morbid. Mortal. Weekly Rep.
43(RR-13):59-64.
|
| 4.
|
Chiang, I.-H.,
J. Suo,
K.-J. Bai,
T.-P. Lin,
K.-T. Luh,
C.-J. Yu, and P.-C. Yang.
1997.
Serodiagnosis of tuberculosis. A study comparing three specific mycobacterial antigens.
Am. J. Respir. Crit. Care Med.
156:906-911[Abstract/Free Full Text].
|
| 5.
|
Cole, R. A.,
H. M. Lu,
Y. Z. Shi,
J. Wang,
T. De-Hua, and A. T. Zhou.
1996.
Clinical evaluation of a rapid immunochromatographic assay based on the 38 kDa antigen of Mycobacterium tuberculosis on patients with pulmonary tuberculosis in China.
Tubercle Lung. Dis.
77:363-368[CrossRef][Medline].
|
| 6.
|
Daniel, T. M.
1996.
Immunodiagnosis of tuberculosis, p. 223-231.
In
W. N. Rom, and S. M. Garay (ed.), Tuberculosis. Little, Brown & Co., Boston, Mass.
|
| 7.
|
Daniel, T. M., and S. M. Debanne.
1987.
The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay.
Am. Rev. Respir. Dis.
135:1137-1151[Medline].
|
| 8.
|
Galloway, Y.,
M. Baker, and M. Brett.
1996.
Tuberculosis increases again in 1995.
N. Z. Public Health Rep.
3:91-93.
|
| 9.
|
Pottumarthy, S.,
A. J. Morris,
A. C. Harrison, and V. C. Wells.
1999.
Evaluation of tuberculin gamma interferon assay: potential to replace the Mantoux skin test.
J. Clin. Microbiol.
37:3229-3232[Abstract/Free Full Text].
|
| 10.
|
Verbon, A.,
G. J. Weverling,
S. Kuijper,
P. Speelman,
H. M. Jansen, and A. H. J. Kolk.
1993.
Evaluation of different tests for the serodiagnosis of tuberculosis and the use of likelihood ratios in serology.
Am. Rev. Respir. Dis.
148:378-384[Medline].
|
| 11.
|
Wilkins, E. G. L.
1998.
Antibody detection in tuberculosis, p. 81-96.
In
P. D. O. Davies (ed.), Clinical tuberculosis. Chapman & Hall Publishing Co., London, United Kingdom.
|
| 12.
|
Wilkins, E. G. L., and J. Ivanyi.
1990.
Potential value of serology for diagnosis of extrapulmonary tuberculosis.
Lancet
336:641-644[CrossRef][Medline].
|
| 13.
|
Wilkinson, R. J.,
K. Haslov,
R. Rappuoli,
F. Giovannoni,
P. R. Narayanan,
C. R. Desai,
H. M. Vordermeier,
J. Paulsen,
G. Pasvol,
J. Ivanyi, and M. Singh.
1997.
Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent.
J. Clin. Microbiol.
35:553-557[Abstract].
|
| 14.
|
Zhou, A. T.,
W.-L. Ma,
P.-Y. Zhang, and R. A. Cole.
1996.
Detection of pulmonary and extrapulmonary tuberculosis patients with the 38-kilodalton antigen from Mycobacterium tuberculosis in a rapid membrane-based assay.
Clin. Diagn. Lab. Immunol.
3:337-341[Abstract].
|
Journal of Clinical Microbiology, June 2000, p. 2227-2231, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Senol, G., Erer, O. F., Yalcin, Y. A., Coskun, M., Gunduz, A. T., Bicmen, C., Ertas, M., Ozkan, S. A.
(2007). Humoral immune response against 38-kDa and 16-kDa mycobacterial antigens in tuberculosis. Eur Respir J
29: 143-148
[Abstract]
[Full Text]
-
Achkar, J. M., Dong, Y., Holzman, R. S., Belisle, J., Kourbeti, I. S., Sherpa, T., Condos, R., Rom, W. N., Laal, S.
(2006). Mycobacterium tuberculosis Malate Synthase- and MPT51-Based Serodiagnostic Assay as an Adjunct to Rapid Identification of Pulmonary Tuberculosis.. CVI
13: 1291-1293
[Abstract]
[Full Text]
-
Sharma, A., Saha, A., Bhattacharjee, S., Majumdar, S., Das Gupta, S. K.
(2006). Specific and Randomly Derived Immunoactive Peptide Mimotopes of Mycobacterial Antigens. CVI
13: 1143-1154
[Abstract]
[Full Text]
-
Benabdesselem, C., Fathallah, D. M., Huard, R. C., Zhu, H., Jarboui, M. A., Dellagi, K., Ho, J. L., Barbouche, R. M.
(2006). Enhanced Patient Serum Immunoreactivity to Recombinant Mycobacterium tuberculosis CFP32 Produced in the Yeast Pichia pastoris Compared to Escherichia coli and Its Potential for Serodiagnosis of Tuberculosis.. J. Clin. Microbiol.
44: 3086-3093
[Abstract]
[Full Text]
-
Kassa-Kelembho, E., Kassa, E., Zandanga, G., Service, Y.-B., Ignaleamoko, A., Talarmin, A.
(2006). Poor Performance of a Novel Serological Test for Diagnosis of Pulmonary Tuberculosis in Bangui, Central African Republic. CVI
13: 702-703
[Abstract]
[Full Text]
-
Field, S. K., Cowie, R. L.
(2006). Lung Disease Due to the More Common Nontuberculous Mycobacteria. Chest
129: 1653-1672
[Abstract]
[Full Text]
-
Pheiffer, C., Betts, J. C., Flynn, H. R., Lukey, P. T., van Helden, P.
(2005). Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv. Microbiology
151: 1139-1150
[Abstract]
[Full Text]
-
Weldingh, K., Rosenkrands, I., Okkels, L. M., Doherty, T. M., Andersen, P.
(2005). Assessing the Serodiagnostic Potential of 35 Mycobacterium tuberculosis Proteins and Identification of Four Novel Serological Antigens. J. Clin. Microbiol.
43: 57-65
[Abstract]
[Full Text]
-
Bothamley, G. H.
(2004). Epitope-Specific Antibody Levels Demonstrate Recognition of New Epitopes and Changes in Titer but Not Affinity during Treatment of Tuberculosis. CVI
11: 942-951
[Abstract]
[Full Text]
-
Okenu, D. M. N., Ofielu, L. O., Easley, K. A., Guarner, J., Spotts Whitney, E. A., Raghunathan, P. L., Stienstra, Y., Asamoa, K., van der Werf, T. S., van der Graaf, W. T. A., Tappero, J. W., Ashford, D. A., King, C. H.
(2004). Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. CVI
11: 387-391
[Abstract]
[Full Text]
-
Okuda, Y., Maekura, R., Hirotani, A., Kitada, S., Yoshimura, K., Hiraga, T., Yamamoto, Y., Itou, M., Ogura, T., Ogihara, T.
(2004). Rapid Serodiagnosis of Active Pulmonary Mycobacterium tuberculosis by Analysis of Results from Multiple Antigen-Specific Tests. J. Clin. Microbiol.
42: 1136-1141
[Abstract]
[Full Text]
-
Imaz, M. S., Comini, M. A., Zerbini, E., Sequeira, M. D., Latini, O., Claus, J. D., Singh, M.
(2004). Evaluation of Commercial Enzyme-Linked Immunosorbent Assay Kits for Detection of Tuberculosis in Argentinean Population. J. Clin. Microbiol.
42: 884-887
[Abstract]
[Full Text]
-
Julian, E., Matas, L., Alcaide, J., Luquin, M.
(2004). Comparison of Antibody Responses to a Potential Combination of Specific Glycolipids and Proteins for Test Sensitivity Improvement in Tuberculosis Serodiagnosis. CVI
11: 70-76
[Abstract]
[Full Text]
-
Conde, M. B., Suffys, P., Lapa e Silva, J. R., Kritski, A. L., Dorman, S. E.
(2004). Immunoglobulin A (IgA) and IgG Immune Responses against P-90 Antigen for Diagnosis of Pulmonary Tuberculosis and Screening for Mycobacterium tuberculosis Infection. CVI
11: 94-97
[Abstract]
[Full Text]
-
Julian, E., Matas, L., Perez, A., Alcaide, J., Laneelle, M.-A., Luquin, M.
(2002). Serodiagnosis of Tuberculosis: Comparison of Immunoglobulin A (IgA) Response to Sulfolipid I with IgG and IgM Responses to 2,3-Diacyltrehalose, 2,3,6-Triacyltrehalose, and Cord Factor Antigens. J. Clin. Microbiol.
40: 3782-3788
[Abstract]
[Full Text]
-
Kameswaran, M., Shetty, K., Ray, M. K., Jaleel, M. A., Kadival, G. V.
(2002). Evaluation of an In-House-Developed Radioassay Kit for Antibody Detection in Cases of Pulmonary Tuberculosis and Tuberculous Meningitis. CVI
9: 987-993
[Abstract]
[Full Text]
-
Florio, W., Bottai, D., Batoni, G., Esin, S., Pardini, M., Maisetta, G., Campa, M.
(2002). Identification, Molecular Cloning, and Evaluation of Potential Use of Isocitrate Dehydrogenase II of Mycobacterium bovis BCG in Serodiagnosis of Tuberculosis. CVI
9: 846-851
[Abstract]
[Full Text]
-
Houghton, R. L., Lodes, M. J., Dillon, D. C., Reynolds, L. D., Day, C. H., McNeill, P. D., Hendrickson, R. C., Skeiky, Y. A. W., Sampaio, D. P., Badaro, R., Lyashchenko, K. P., Reed, S. G.
(2002). Use of Multiepitope Polyproteins in Serodiagnosis of Active Tuberculosis. CVI
9: 883-891
[Abstract]
[Full Text]
-
Gounder, C., de Queiroz Mello, F. C., Conde, M. B., Bishai, W. R., Kritski, A. L., Chaisson, R. E., Dorman, S. E.
(2002). Field Evaluation of a Rapid Immunochromatographic Test for Tuberculosis. J. Clin. Microbiol.
40: 1989-1993
[Abstract]
[Full Text]
-
Samanich, K., Belisle, J. T., Laal, S.
(2001). Homogeneity of Antibody Responses in Tuberculosis Patients. Infect. Immun.
69: 4600-4609
[Abstract]
[Full Text]
-
Landowski, C. P., Godfrey, H. P., Bentley-Hibbert, S. I., Liu, X., Huang, Z., Sepulveda, R., Huygen, K., Gennaro, M. L., Moy, F. H., Lesley, S. A., Haak-Frendscho, M.
(2001). Combinatorial Use of Antibodies to Secreted Mycobacterial Proteins in a Host Immune System-Independent Test for Tuberculosis. J. Clin. Microbiol.
39: 2418-2424
[Abstract]
[Full Text]
-
Lodes, M. J., Dillon, D. C., Mohamath, R., Day, C. H., Benson, D. R., Reynolds, L. D., McNeill, P., Sampaio, D. P., Skeiky, Y. A. W., Badaro, R., Persing, D. H., Reed, S. G., Houghton, R. L.
(2001). Serological Expression Cloning and Immunological Evaluation of MTB48, a Novel Mycobacterium tuberculosis Antigen. J. Clin. Microbiol.
39: 2485-2493
[Abstract]
[Full Text]